Main Street Financial Solutions LLC Sells 12,800 Shares of Urogen Pharma $URGN

Posted by Francis Steltz on Aug 19th, 2026

Main Street Financial Solutions LLC lowered its position in shares of Urogen Pharma (NASDAQ:URGN – Free Report) by 61.0% in the second quarter, Holdings Channel reports. The institutional investor owned 8,190 shares of the company’s stock after selling 12,800 shares during the period. Main Street Financial Solutions LLC’s holdings in Urogen Pharma were worth $301,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. AQR Capital Management LLC grew its stake in shares of Urogen Pharma by 347.5% in the first quarter. AQR Capital Management LLC now owns 114,066 shares of the company’s stock valued at $1,262,000 after acquiring an additional 88,577 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Urogen Pharma by 7.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after purchasing an additional 1,653 shares in the last quarter. Jane Street Group LLC boosted its holdings in Urogen Pharma by 94.3% in the 1st quarter. Jane Street Group LLC now owns 51,177 shares of the company’s stock valued at $566,000 after purchasing an additional 24,839 shares during the period. Cetera Investment Advisers bought a new stake in Urogen Pharma in the 2nd quarter valued at about $361,000. Finally, JPMorgan Chase & Co. grew its position in shares of Urogen Pharma by 5.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 390,364 shares of the company’s stock worth $5,348,000 after purchasing an additional 19,405 shares in the last quarter. Institutional investors own 91.29% of the company’s stock.

Urogen Pharma Stock Down 0.4%

URGN stock opened at $48.92 on Wednesday. The company’s 50-day moving average price is $39.38 and its two-hundred day moving average price is $28.55. The firm has a market cap of $2.39 billion, a P/E ratio of -24.71 and a beta of 1.57. Urogen Pharma has a 12 month low of $15.86 and a 12 month high of $49.67.

Urogen Pharma (NASDAQ:URGN – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The firm had revenue of $72.46 million for the quarter, compared to the consensus estimate of $63.55 million. Equities analysts predict that Urogen Pharma will post -0.2 EPS for the current year.

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the company’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the sale, the insider directly owned 119,763 shares in the company, valued at $4,790,520. This represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 25,222 shares of company stock worth $892,661 in the last three months. 4.80% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. HC Wainwright raised their target price on shares of Urogen Pharma from $45.00 to $75.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $44.00 price target on shares of Urogen Pharma in a research note on Wednesday, July 15th. Oppenheimer increased their price target on Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Friday, July 17th. Finally, UBS Group reaffirmed a “buy” rating on shares of Urogen Pharma in a report on Thursday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $50.38.

Check Out Our Latest Stock Analysis on Urogen Pharma

Urogen Pharma Profile

(Free Report)

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.